Skip to main content
TipRanks
Go Ultimate75% OFF

EBM Technologies Incorporated (8409) AI Stock Analysis

TW:8409

EBM Technologies Incorporated

(TPEx:8409)

Select Model
Rating:48Neutral
Price Target:TWD 17.00â–¼(-6.08% Downside)
Action:initiatedcoverage
Date:11/10/26

Weak financial performance from revenue volatility and negative cash flows is the main drag, reinforced by bearish technical signals; moderate valuation provides only partial support.

Positive Factors
Conservative LeverageLower leverage gives EBM Technologies greater financial flexibility and reduces balance-sheet risk over the next several quarters. A sizeable equity base can help absorb earnings volatility, preserve borrowing capacity, and support ongoing operations without excessive dependence on external financing.
Negative Factors
Revenue Volatility and DeclineUnstable and declining revenue reduces visibility into the company’s durable demand profile and makes operating results harder to plan. Prolonged top-line weakness could limit scale benefits, weaken reinvestment capacity, and prevent the strong gross margin from translating into consistently stronger earnings.

EBM Technologies Incorporated (8409) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%TW:8409-16.59%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 576.00M
Dividend Yield
―
Average Volume (3M)
8,627
Price to Earnings (P/E)
47.4
Beta (1Y)
0.30
Revenue Growth
-31.90%
EPS Growth
-73.49%
Country
TW
Employees
150
Sector
General
Sector Strength
55
Industry
Medical - Healthcare Information Services

EBM Technologies Incorporated Business Overview & Revenue Model

Company Description

Established in 1988 and headquartered in Taipei, Taiwan, EBM Technologies Incorporated is dedicated to developing and commercializing sophisticated software and integrated solutions for the global healthcare sector. The company's core offerings inclu...

EBM Technologies Incorporated Financial Statement Overview

Summary

Mixed results with volatile revenue, sharply negative cash flows, and thin margins outweighing a stable low-leverage balance sheet.

Income Statement

47Neutral

Balance Sheet

71Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue283.98M253.11M280.95M206.15M383.88M194.93M
Gross Profit201.60M174.46M178.04M154.94M184.43M131.29M
EBITDA96.85M23.18M20.68M3.77M22.71M-9.68M
Net Income32.64M7.80M2.14M-14.01M4.00M-21.86M
Balance Sheet
Total Assets422.35M436.02M559.67M486.23M468.51M600.04M
Cash, Cash Equivalents and Short-Term Investments138.16M130.83M223.86M149.91M142.12M156.71M
Total Debt77.76M66.16M84.32M125.49M87.16M123.23M
Total Liabilities122.15M117.05M246.22M179.57M148.91M290.16M
Stockholders Equity300.21M318.97M313.45M306.66M319.60M309.88M
Cash Flow
Free Cash Flow14.37M-75.31M118.69M-12.13M10.23M-29.81M
Operating Cash Flow15.88M-72.96M121.79M-9.84M19.95M-19.20M
Investing Cash Flow-1.17M1.25M-4.20M-13.37M-3.75M9.48M
Financing Cash Flow-7.68M-19.89M-45.80M29.48M-34.58M71.96M

EBM Technologies Incorporated Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:8409 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:8409TW:840948NeutralTWD 568.00M47.37――-31.90%-73.49%

* General Sector Average

Performance Comparison

-60%-40%-20%0%TW:8409TW:6665TW:6758TW:6999TW:7726TW:7835Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:8409 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:8409EBM Technologies Incorporated18.10-3.60-16.59%
TW:6665Healthconn Corp.15.60-5.15-24.83%
TW:6758A-SPINE Asia Co., Ltd.29.45-8.22-21.81%
TW:6999Han Biomedical, Inc.24.45-6.02-19.75%
TW:7726CARILEX MEDICAL INC.32.15-3.95-10.94%
TW:7835H2U Corporation14.55-25.40-63.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026